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a b s t r a c t
Enzyme-catalyzed enantiomer discrimination is still a great challenge for the development of industrial
pharmaceutical processes. For the resolution of ibuprofen, naproxen and ketoprofen racemates, three
major anti-inflammatory drugs, only lipases from Candida rugosa present a high selectivity if solvent
and surfactant use is discarded. However, their catalytic activities are too low. In the present work, we
demonstrate that the lipase Lip2p from the yeast Yarrowia lipolytica has a higher catalytic activity than
C. rugosa lipases to hydrolyze the ethyl esters of ibuprofen, naproxen and ketoprofen, but its selectivity
is not sufficient [E = 52 (S); 11 (S) and 1.5 (R) respectively]. The enantioselectivity was further improved
by site-directed mutagenesis, targeted at the substrate binding site and guided by molecular modelling
studies. By investigating the binding modes of the (R)- and (S)-enantiomers in the active site, two amino
acid residues located in the hydrophobic substrate binding site of the lipase, namely residues 232 and
235, were identified as crucial for enantiomer discrimination and enzyme activity. The (S) enantioselec-
tivity of Lip2p towards ethyl ibuprofen esters was rendered infinite (E! 300) by replacing V232
by an A or C residue. Substitution of V235 by C, M, S, or T amino acids led to a great increase in the
(S)-enantioselectivity (E! 300) towards naproxen ethyl ester. Finally, the variant V232F enabled the
efficient kinetic resolution of ethyl ketoprofen ester enantiomers [(R)-enantiopreference; E! 300]. In
addition to the increase in selectivity, a remarkable increase in velocity by 2.6, 2.7 and 2.5 times,
respectively, was found for ibuprofen, naproxen and ketoprofen ethyl esters.
1. Introduction
a-Substituted aryl and alkyl carboxylic acids are important
intermediates encountered in the synthetic pathways of numerous
drugs, such as prostaglandin, prostacyclin, semi-synthetic
penicillin and thiazolium salts. Among them, derivatives of
2-arylpropionic acids, 2-(4-isobutylphenyl)propionic acid, com-
monly known as ibuprofen, 2-(6-methoxy-2-naphthyl)propionic
acid, also called naproxen, and 2-(3-benzoylphenyl)propionic acid,
commonly named ketoprofen are regularly used as non-steroid
anti-inflammatory drugs (NAIDs) in the treatment of headaches,
rheumatoid arthritis, cephalalgia or muscular cells.1
All of these molecules have a stereogenic centre at the a-posi-
tion of the carboxylic function, leading to the co-existence of two
enantiomers. In most cases, only one enantiomer has the required
biological activity. For instance, the (S)-enantiomer of ibuprofen is
160 times more active than its (R)-counterpart.2,3 Similarly, the (S)-
enantiomer of naproxen is 28 times more active than the (R)-
form.4 The anti-inflammatory properties of ketoprofen are princi-
pally due to the (S)-enantiomer, whereas the (R)-enantiomer has
side effects.5 The use of only the active enantiomer is thus often
privileged whenever it can be obtained in a pure form. Therefore,
a major challenge consists of separating these enantiomers to
obtain a pure biologically active substance. Classical methods used
to obtain pure enantiomers, such as chemical asymmetric synthe-
sis, stereoselective crystallization or chiral chromatography, are
usually expensive. The use of highly enantioselective enzymes
(enantioselectivity value, E, ratio of reaction rates for both
enantiomers higher than 200) is thus an appealing alternative to
separate such enantiomers.
⇑ Corresponding authors at: Laboratoire d’Ingénierie des Systèmes Biologiques et
Procédés, Institut National des Sciences Appliquées, 135 Avenue de Rangueil, 31077
Toulouse Cedex 4, France. Tel.: +33 (0)5 61 55 94 39; fax: +33 (0)5 61 55 94 00.
E-mail addresses: alain.marty@insa-toulouse.fr (A. Marty), sophie.duquesne@
insa-toulouse.fr (S. Duquesne).
Several enzymatic routes have been explored for obtaining
enantiopure profens and profenols,6 such as use of alcohol dehy-
drogenases,7–10 arylmalonate decarboxylases, ene reductases11
and nitrilases, either based on the kinetic resolution of racemates
or asymmetrization of prochiral precursors.
In the case of 2-arylpropionic acids, lipases have been shown to
be good candidates to catalyze the kinetic resolution of (RS)-race-
mates, either by hydrolysis of an ester or by esterification of the
acid form. Several lipases from various origins (plant and micro-
bial) have already been reported for the resolution of ibuprofen,
naproxen and ketoprofen esters or the corresponding acids.
Lipases from Rhizomucor miehei,12 Carica papaya13 or evolved
Candida antarctica lipase,14,15were previously tested for the resolu-
tion of (RS)-ibuprofen racemate by either hydrolysis or esterifica-
tion reactions. However, all three of them led to low
enantioselectivity (E < 200). The lipase from C. rugosa (formerly C.
cylindracea) was shown to be the best enzyme to discriminate
(RS) ibuprofen racemate.16–28 The best result, considering the
enantioselective hydrolysis of ibuprofen racemate using free
enzyme, presents an enantioselectivity of 247.16 Nevertheless, this
high E value was obtained by the addition of N,N-dimethylfor-
mamide, which is highly toxic.
C. rugosa, C. papaya and R. miehei free lipases were also studied
for the hydrolysis of naproxen ester racemate.13,17,29–35 Among
them, lipases from C. rugosa were found to be the most enantiose-
lective enzymes for this reaction (E = 397).32 Lysophospholipase
and carboxylesterase were also studied for the resolution of the
naproxen ester:36,37 the carboxylesterase NP produced by Bacillus
subtilis gave a high enantioselectivity (E = 500), nevertheless, this
high enantioselectivity was obtained by the addition of formalde-
hyde, which is highly toxic.37
Lipases from Thermogota maritima,38 Aspergillus niger, Aspergil-
lus terreus, Fusarium oxysporum,39 Mucor javanicus,40,41 R.
miehei,40,41 Trichosporon laibacchii,42 Pseudomonas cepacia,4 C.
papaya,13 B. subtilis43 and from C. rugosa19 were previously tested
for the resolution of (RS)-ketoprofen racemate. However, all of
them led to poor enantioselectivity (E < 200). In order to improve
upon the enantioselectivity of the lipase from C. rugosa (E = 27),19
various strategies were employed, such as enzyme immobiliza-
tion44–46 or two step acetone treatment18 but only an enantioselec-
tivity of 153 was reached.44
The enantioselectivity of Serratia marcescens lipase was
improved (from 63 to 1084) by the addition of a surfactant Brij
92V.47 Similarly, the enantioselectivity of Pseudomonas sp.
KCTC10122BP lipase48 and Acinetobacter lipase49 were found to
be superior to 200 (absolute and 752, respectively) but with use
of triton X-100. However, addition of a surfactant generally leads
to a complexification of the purification process, and to high pro-
duction costs.
Variants of C. Antarctica lipase CalB,14 and of the recently meta-
genome-isolated esterase Est2550 enabled an enantioselectivity
higher than 200, but very low concentrations of the substrate were
used. It appears that the lipases from C. rugosa are good candidates
for the resolution of the three substrates considered. Despite their
significant enantioselectivity, the catalytic efficiencies of the
lipases from C. rugosa are relatively low, almost one order of mag-
nitude lower than that of Lip2p lipase from the oleaginous yeast Y.
lipolytica51,52 during the resolution of 2-bromophenyl acetic acid
ester.
Herein we tried to identify new enzymes able to highly discrim-
inate between the (R)- and (S)-enantiomers of ibuprofen, naproxen
and ketoprofen ethyl esters, and with high catalytic efficiency. The
Y. lipolytica Lip2p lipase was reported to catalyze the resolution of
ibuprofen racemate with a low enantioselectivity (E = 56).53
Moreover, variants of this lipase have been shown to have a high
catalytic efficiency and enantioselectivity for the resolution of
(RS)-2-bromophenyl acetic acid ester racemate.52,54 Enzyme vari-
ants with increased or totally inverted enantioselectivity, concomi-
tant with a remarkable increase in velocity, were also obtained.55
The performances of the Y. lipolytica wild-type lipase is compared
to wild-type lipases (CRL 1 and 4) from C. rugosa, which has been
described in the literature as being one of the most efficient
enzymes for the resolution of the considered racemates.16,19,34,44
In view of the results, the library of Lip2p variants from Y. lipolytica,
previously built for the resolution of the (RS)-2-bromophenyl
acetic acid ester racemate, was tested on the three molecules and
molecular modelling was used to identify new targets for site-
directed mutagenesis and to understand the role of amino acid
changes on the selective recognition of the (RS)-enantiomers of
each racemate.
2. Results and discussion
2.1. Resolution of (RS)-ibuprofen naproxen and ketoprofen
ethyl ester racemates using wild-type lipases
The reaction scheme of the enantioselective lipase-catalyzed
hydrolysis of the racemic mixture of three different esters is pre-
sented in Figure 1. Wild-type Lip2p from Y. lipolyticawas compared
to C. rugosa lipases (CRL 1 and 4), the most efficient enzymes
known to date for the resolution of ibuprofen, naproxen and keto-
profen racemates. CRL lipases were produced in recombinant form
by a strain of Y. lipolytica as pure isoform of CRL1 and CRL4.51
All three lipases were produced using the Y. lipolytica strain
JMY1212,56 in which the lipase encoding gene is introduced in
the genome at the zeta docking platform, leading to good repro-
ducibility of the enzyme expression and enabling a comparison
of enzyme variant activities directly from the supernatant.55 In
addition, this strain is deleted for the main extracellular protease
(XPR2) and the main extracellular lipases (Lip2p, 7 and 8), which
in turn enables for the supernatant to be obtained with high pro-
tein purity.57–59 It was checked that no activity with this strain
was obtained whatever the used racemate (data not shown).
The protein contents of Y. lipolytica supernatant containing
Lip2p, CRL1 or CRL4 were compared by SDS page (data not shown).
Enzyme concentration was estimated as 5 times lower for CRL1
and CRL4 expressed in Y. lipolytica compared with Lip2p. The two
enzymes of C. rugosa were then 10 times concentrated for compar-
ison. Enzymes were then tested during the hydrolysis of ibuprofen,
naproxen and ketoprofen ethyl esters (Table 1).
Our results confirmed that C. rugosa lipase CRL1 was an efficient
enzyme with regards to the enantioselectivity to discriminate
between the enantiomers of ibuprofen, naproxen and ketoprofen
ethyl esters, with a total preference for the (S)-enantiomer. Never-
theless, whatever the racemate and even with a 10 times concen-
tration of the supernatant, the rate of reaction was low. Despite
sharing 81 % of identity with CRL1, lipase CRL4 was only active
on ketoprofen ethyl ester with a total preference for the (R)-enan-
tiomer. This reverse enantioselectivity of CRL1 and CRL4 was
already observed during the resolution of bromophenyl acetic acid
ester racemates.51
Wild-type Lip2p lipase from Y. lipolytica showed a clear prefer-
ence for the (S)-enantiomer in the hydrolysis of ibuprofen ethyl
ester racemate (E = 52, Table 1). This result is in agreement with
the E value of 56 obtained in previous studies53 of esterification
of ibuprofen using immobilized Lip2p lipase. The positive influence
of the para substitution of the phenyl group on the E value of Lip2p
lipase had already been observed for the transesterification of 2-
bromo-phenyl acetic ethyl and 2-bromo-p-tolylacetic ethyl ester.60
The presence of a methyl group at the para-position of the phenyl
group led to an improvement in the selectivity of Lip2p lipase
towards the (S)-enantiomer with an E value of 28 against an E
value of 3 in the absence of the methyl group.60 The presence of
an isobutyl group at the para position of the phenyl group in
ibuprofen ester seemed to have the same effect.
The steric hindrance of the naproxen ethyl ester in the Lip2p
lipase active site is clearly more important than that of 2-bro-
mophenyl-acetic and ibuprofen ethyl esters, due to the presence
of the naphthalene group. As a consequence, the rate of hydrolysis
of the preferred (S)-enantiomer by wild-type Lip2p is 4 times lower
than the one observed for (S)-ibuprofen ethyl ester (Table 1). Con-
versely, the poorly-hydrolyzed (R)-enantiomer was slightly better
recognized, leading to an enantioselectivity 5 times lower (E = 11).
The rate of hydrolysis of the (S)-enantiomer of ethyl ketoprofen
by wild-type Lip2p is 4 times lower than the one observed for the
(S)-naproxen ethyl ester, and 16 times lower compared to the (S)-
ibuprofen ethyl ester. The (R)-enantiomer of ethyl ketoprofen was
the best recognized enantiomer by Lip2p (E = 1.5). Moreover, the
catalytic efficiency of Lip2p for the best recognized enantiomer of
ibuprofen, naproxen and ketoprofen ethyl ester is one order of
magnitude higher than the one obtained with CRL1. Only CRL4,
during the ethyl ketoprofen ester resolution, possessed a catalytic
efficiency in the same range to that observed with Lip2p.
2.2. Resolution of (RS)-ibuprofen ethyl ester racemate by Lip2p
enzyme variants
With the aim of improving the enantioselectivity of the Lip2p
lipase from Y. lipolytica for the resolution of the (RS)-ibuprofen
ethyl ester racemate, a previously built library of enzyme vari-
ants54,55 was screened. This library of single enzyme variants
results from a rational engineering strategy that consisted in
applying site-directed mutagenesis to 5 amino acids (T88, V94,
V285, V232 and D97) located in the substrate binding site. Among
these Lip2p variants, position 232 was found to be crucial in terms
of the activity and the enantioselectivity during the resolution of 2-
bromophenyl acetic acid esters.54 In total, 25 single enzyme vari-
ants of Lip2p were tested for their ability to resolve the ibuprofen
ethyl ester racemate (19 single variants at position 232 and
enzyme variants D97A, T88S, V94A, V94L, V285A, and V285L). A
double substituted enzyme variant (D97A-V232F), with highly
inverted enantioselectivity towards 2-bromo phenyl acetic acid
esters55 was also tested. It was checked by SDS page gel protein
that all of the variants tested are expressed at the same level than
the wild-type enzyme (data not shown).
Enzyme variant T88S and enzyme variants at position 94 pre-
sent lower activity than the wild-type Lip2p and no change in
selectivity. Enzyme variant V285A presents a similar behavior as
the wild-type enzyme, whereas V285L and D97A variants are no
more active. The double substituted enzyme variant D97A-V232F
was not active on ethyl ibuprofen, whereas it displayed a total
preference for the (R)-enantiomer of 2-bromophenyl-acetic octyl
ester and 4.5 times enhancement of its activity.55
As already observed during the kinetic resolution of 2-bromo-
arylacetic acid esters, position 232 appears to be crucial for the dis-
crimination between ibuprofen enantiomers. Indeed, three Lip2p
variants with an amino acid change at this position 232 (V232A,
V232C and V232S) present a higher enantioselectivity than the
wild-type enzyme. All of them showed an improvement in enan-
tioselectivity, from an E value of 52 for the wild-type enzyme to
an E value higher than 200 for the enzyme variants; this was due
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Figure 1. Reaction scheme of the lipase-catalyzed resolution of (RS)-ethyl ester racemate of ibuprofen, naproxen and ketoprofen by a (S)- or (R)-enantioselective lipase (up
and down reaction, respectively).
Table 1
Comparison between activities and selectivities of Lip2p from Y. lipolytica and C. rugosa lipases for the hydrolysis of ethyl-ibuprofen, ethyl-naproxen and ethyl-ketoprofen. The
hydrolysis was performed in a biphasic medium: 750 lL of decane containing 50 mM of ester racemate, 750 lL of enzyme supernatant (or the concentrate supernatant for CRL
lipases), stirred at room temperature for 100 h
Ethyl ibuprofen Ethyl naproxen Ethyl ketoprofen
viS viR E viS viR E viS viR E
(lmol"h#1"mL#1) (lmol"h#1"mL#1) (viS/viR) (lmol"h#1"mL#1) (lmol"h#1"mL#1) (viS/viR) (lmol"h#1"mL#1) (lmol"h#1"mL#1) (viS/viR) or (viS/viR)
CRL1 10X 0.28 0 >200 (S) 0.15 0 >200 (S) 0.06 0 >200 (S)
CRL4 10X 0 0 Nd 0 0 Nd 0 0.99 >200 (R)
Lip2p 1X 1.56 0.03 52 (S) 0.42 0.04 11 (S) 0.11 0.16 1.5 (R)
Nd = not determined.
to a better hydrolysis of the preferred (S)-enantiomer (2.2–2.6
times higher) concomitant to a lower hydrolysis of the poorly rec-
ognized (R)-enantiomer (Table 2). Enzyme variants V232A and
V232C were no more able to recognize the (R)-enantiomer,
whereas enzyme variant V232S exhibits only a lower recognition
of the poorly recognized (R)-enantiomer (2.3 times lower than
wild-type Lip2p). In addition to the gain in enantioselectivity, a
remarkable increase in velocity was observed for the three variants
(2.2–2.6 times increase). The best enzyme was the enzyme variant
V232A (E! 300 with an initial rate of hydrolysis of the (S)-enan-
tiomer of 4.1 lmol"h#1"mL#1).
During the resolution of 2-bromo-phenyl-acetic octyl esters by
Lip2p lipases, the best enzyme variant was found to be the V232S
enzyme variant,54 with an E value !200.
From molecular docking studies, it was assumed that the bulky
bromine atom, facing V232 for the (S)-enantiomer, was involved in
the discrimination of the enantiomers. The size of this amino acid
thus appeared to be crucial for the enantioselectivity. It is notewor-
thy that ibuprofen and 2-bromophenyl-acetic esters are rather
similar in structure. The bromine atom present at the a-position
of the carboxylic acid in 2-bromophenyl-acetic ester is replaced
in ibuprofen by a methyl group, which presents similar steric hin-
drance. From our results, it appears that the size of the amino acid
at position 232 is clearly more important than its polarity. Substi-
tution of the valine present in the wild-type Lip2p lipase by smaller
amino acid residues such as A, C or S enables a better recognition of
the (S)-enantiomer and a poorer recognition of the (R)-enantiomer.
However, enzyme variant V232G is no more active on ethyl ibupro-
fen whereas it was found to be more efficient and selective during
the hydrolysis of 2-bromophenyl-acetic octyl esters.54 As already
observed with 2-bromophenyl-acetic octyl ester, the performance
of the enzyme variant V232T is similar to that of the wild-type
enzyme. Despite the low catalytic efficiency, enzyme variants
V232L, V232I, V232F exhibited enantioselectivity inversion during
2-bromophenyl-acetic octyl ester resolution.54 Replacement of the
valine by a bulkier amino acid such as L, I or F led to enzyme inac-
tivation in the kinetic resolution of ibuprofen.
Using molecular modelling techniques, we constructed three-
dimensional models of the covalent intermediates of Lip2p with
the (RS)-enantiomers of ibuprofen ethyl ester (Fig. 2).
Docking studies revealed distinct binding conformations for the
(RS)-enantiomers, which differed in the orientation of the aromatic
ring, thus impacting the formation of hydrogen bonding interac-
tions between ibuprofen ethyl ester and the oxyanion hole defined
by L163 and T88. Only one hydrogen bond was found between the
(R)-enantiomer of ibuprofen ethyl ester and oxyanion residues of
wild-type Lip2p, whereas two hydrogen bonds were observed for
the (S)-enantiomer (Fig. 3).
This could provide some explanation regarding the (S)-enan-
tioselectivity of wild-type Lip2p toward kinetic resolution of the
ibuprofen ethyl ester. Mutation of V232 by smaller amino acid resi-
dues such as A, C or S, provides more space to better accommodate
the (S) enantiomer of ibuprofen ethyl ester in the catalytic site
(Fig. 2B), with a slight reorientation of the aromatic ring that favors
the formation of; (i) hydrogen bonding interactions between resi-
dues from the oxyanion hole and the carbonyl group from the ethyl
ester (Fig. 3); and (ii) additional van der Waals interactions
between I231 and the isobutyl group. Conversely, mutation of
V232 did not alter binding mode of the (R)-enantiomer in compar-
ison with that observed in wild-type enzyme.
2.3. Resolution of (RS)-naproxen ethyl ester racemate by Lip2p
enzyme variants
The same strategy used for the resolution of ibuprofen ethyl
ester racemate was applied for the resolution of naproxen ethyl
ester racemate. The same library of 25 enzyme variants of Lip2p
lipase from Y. lipolytica was tested. As previously observed for
ibuprofen, an amino acid change at positions 88, 94, 97 and 285
had either a neutral or detrimental effect on the enzyme activity
and selectivity. Changing V232 by smaller amino acid residues
such as A, C or S did not improve either the activity or the selectiv-
ity of the enzyme. The hydrolysis rate of the preferred (S)-enan-
tiomer was even lower than that of the wild-type Lip2p lipase
(data not shown). If a bulkier amino acid residue, such as a L, I or
F, was introduced at this position, the activity was completely lost.
In conclusion, no improvement in either the activity or in the enan-
tioselectivity, was obtained using this library of enzyme variants.
In order to provide structural insight to improve upon selectiv-
ity and activity of Lip2p lipase toward the resolution of naproxen
ethyl ester racemate, a molecular modelling study was carried
out. The energy-minimized covalent intermediates of Lip2p with
the (RS)-enantiomers of naproxen ethyl ester were built. Molecular
docking was carried out to explore accessible conformational space
of both enantiomers in the active site pocket. The top scoring fits
identified for each enantiomer were then compared (Fig. 4A). The
binding mode of the (R)-enantiomer of naproxen ethyl ester was
found to be similar to that observed for the (R)-ibuprofen ethyl
ester. Conversely, the binding mode of the (S)-enantiomer was
found to be significantly different from that observed for ibuprofen
ethyl ester. In this case, the bulkier naphthalene moiety binds in a
small pocket near V235. It thus appears that introduction of an
amino acid mutation at this position could help further improve
the selective recognition of the (S)-enantiomer.
On the basis of this computational study, position 235 was
mutated by all 19 possible amino acids. It was checked by SDS
PAGE that all the variants tested are expressed at the same level
than the wild-type enzyme (data not shown).
This position 235 was found to be crucial for the activity and
enantioselectivity of the enzyme during the naproxen ethyl esters
hydrolysis (Table 3). Indeed, eight enzyme variants presented both
an increase in activity and enantioselectivity.
The enantioselectivity was shown to increase due to a concomi-
tant increase in the hydrolysis rate of the preferred (S)-enantiomer
and decreased in the hydrolysis rate of the poorly-recognized (R)-
enantiomer. One enzyme variant, namely V235L, exhibited a spec-
tacular increase for the hydrolysis rate of the (S)-enantiomer (6.5
times higher than the activity of the wild-type enzyme). Neverthe-
less, since its initial rate of hydrolysis of the (R)-enantiomer was
also higher, the resulting E value is only twice the E value of
wild-type Lip2p lipase. Enzyme variants V235C, V235M, V235S
and V235T were no more able to recognize the (R)-enantiomer,
leading to an E! 300. The two best enzyme variants isolated were
V235C and V235S, which exhibited a 2.7 times increase in activity
for the best recognized (S)-enantiomer and an E value higher than
200.
Moreover, to confirm that the (R)-enantiomer of the naproxen
was absolutely not hydrolyzed by the Lip2p V235S variant, a first
hydrolysis of the racemic mixture was conducted with this variant
Table 2
Comparison of activity and selectivity of wild-type Lip2p lipase from Y. lipolytica and
its variants during hydrolysis of (RS)-ibuprofen ethyl ester racemate. The hydrolysis
was performed in a biphasic medium:750 lL of decane containing 50 mM of ester
racemate, 750 lL of enzyme supernatant (or the concentrate supernatant for CRL
lipases), stirred at room temperature for 100 h
viS (lmol"h#1"mL#1) viR (lmol"h#1"mL#1) E (viS/viR)
Wild-type V232 1.56 0.030 52
V232A 4.07 0 >300
V232C 3.55 0 >300
V232S 3.44 0.013 263
and the organic phase was recovered after 60 h reaction. This
organic phase, which was almost only composed of the (R)-enan-
tiomer of the naproxen, was put into contact with fresh enzyme
(Lip2p V235S). No hydrolysis of the (R)-enantiomer was observed
over a period of 50 h.
Detailed analysis of molecular modelling results indicated that
substitution of V235 by a small and polar amino acid residue such
as S, T or C, favors the formation of an additional hydrogen bonding
interaction between the amino acid side chain at position 235 and
the oxygen of the methoxy group from the (S)-enantiomer
(Fig. 4B), leading to an increase of the affinity for the (S)-enan-
tiomer over the (R)-enantiomer and thus an enhanced enantiose-
lectivity, as confirmed by experimental data.
The enzyme variants at the position V235 were tested for the
resolution of ethyl ibuprofen; these enzyme variants have a low
activity compared to the wild type Lip2p. For example, the enzyme
variant V235S and V235C are 7 and 15 times less active than the
wild type enzyme, respectively. The same negative result was
obtained during the resolution of the (RS)-2-bromophenyl acetic
acid ester racemate.
Figure 2. Representation of (R)- and (S)-ibuprofen ethyl ester enantiomers covalently bound to catalytic S162 of wild-type Lip2p (A) and V232A enzyme variant (B). The (S)
(blue) and (R) (magenta) enantiomers are shown. The catalytic triad (D230, S162, H289) is shown as yellow sticks, residues forming the oxyanion hole (L163 and T88) are
colored in cyan, amino acid residue at position 232 is colored in green, and I231 in orange. For clarity, hydrogens are not represented.
Figure 3. Representation of interactions between (R)- or (S)-ibuprofen ethyl ester with wild-type Lip2p enzyme. The drawing has been performed using Ligplot.
2.4. Resolution of (RS)-ketoprofen ethyl ester racemate by Lip2p
enzyme variants
The two combined libraries used previously were tested.
Enzyme variant T88S, V285A and enzyme variants at position
V94A had lower activity than the wild-type Lip2p and no change
in selectivity. Enzyme variant V285L, D97A are not more active.
The two positions V232 and V235, were found to be crucial for
both the activity and enantioselectivity of the enzyme towards
ethyl ketoprofen (Table 4). Substitution of the valine in position
232 present in the wild-type Lip2p by a smaller amino acid residue
such as S (and to a lesser extent A) enables a better recognition of
the (S)-enantiomer (6 times) and a poorer recognition of the (R)-
enantiomer (3 times), resulting in an inversion of preferred enan-
tiomer. The single enzyme variant V235A and mainly V235G pre-
sent the same behavior with an inversion of the preferred
enantiomer and a medium enantioselectivity. Nevertheless, the
activity of the V235G variant is twice as high than the one obtained
with variant V232S. The double enzyme variant V232S-V235G was
constructed but the kinetics and enantioselectivity became lower
than the wild-type lipase.
Regarding the enantioselective hydrolysis of ketoprofen ethyl
ester, the best enzyme was the enzyme variant V232F (E! 300
with an initial rate of hydrolysis of the (R)-enantiomer of
0.4 lmol"h#1"mL#1). As observed during the 2-bromo-arylacetic
acid ester resolution, a substitution of valine 232 by a bulky F anni-
hilates the conversion of the (S)-enantiomer whereas the recogni-
tion for the (R)-enantiomer increases (Table 4 and Fig. 5). The
double mutation D97A-V232F was interesting in the case of the
resolution of the 2-bromo-arylacetic acid ester,61 but in this case
the double mutation is useless, since the monoenzyme variant
V232F presents the same enantioselectivity while the rate is
slightly higher for the monoenzyme variant (Table 4).
3. Conclusion
Herein we have identified new enzymes for the kinetic resolu-
tion of ibuprofen, naproxen and ketoprofen racemates, three mole-
cules of interest for the pharmaceutical industry. Until now, only
lipases from C. rugosa have been reported to be efficient for this
purpose if we exclude solvent and surfactant use. However, if their
enantioselectivity is high, their catalytic efficiency remains very
low. Herein, the lipase Lip2p, efficiently extracellularly produced
by the yeast Y. lipolytica, was shown to have reasonable selectivity
and one order of magnitude higher activity than the lipase CRL1
from C. rugosa during hydrolysis of ibuprofen, naproxen and keto-
profen ethyl esters. The enantioselectivity of this Lip2p was
improved by site-directed mutagenesis experiments targeted to
the substrate binding site, guided by molecular modelling based
on the molecular docking of the (R)- and (S)-enantiomers of the
substrates in the active site. The nature of the amino acids at posi-
tions 232 and 235, localized in the hydrophobic substrate binding
site, were identified as being crucial for the enantioselectivity of
the resolution of these three racemates. The enantioselectivity of
Lip2p towards ethyl ibuprofen was increased from 52 for the
wild-type enzyme to an enantioselectivity higher than 300 for
the variants V232A and V232C. Mutations of V235 to C, M, S, or
T lead to a tremendous increase in enantioselectivity, from 11 to
an E! 300 for the resolution of naproxen ethyl ester racemate.
One variant of a lipase from Y. lipolytica with an infinite enantios-
electivity was found (V232F) with an (R)-enantioselectivity for the
resolution of ethyl ketoprofen ester racemate, while the wild-type
lipase had a poor enantioselectivity of 1.5. In addition to the gain in
selectivity, a remarkable increase in velocity was demonstrated
(at least 2.5 times increase) for all substrates. These results
demonstrate the high potential of rational engineering to create
Figure 4. Representation of (R)- and (S)-naproxen ethyl ester enantiomers covalently bound to catalytic S162 of (A) wild-type Lip2p and (B) Lip2p V235S variant. The (S)
(blue) and (R) (magenta) enantiomers are shown; The catalytic triad is shown in yellow, residues forming the oxyanion hole are colored in cyan and residues 232 and 235 are
colored in green. For clarity, hydrogens are not represented.
Table 3
Comparison of activity and selectivity of wild-type Lip2p and the best enzyme
variants on position V235 during hydrolysis of (RS)-naproxen ethyl ester racemate.
The hydrolysis was performed in a biphasic medium:750 lL of decane containing
50 mM of ester racemate, 750 lL of enzyme supernatant (or the concentrate
supernatant for CRL lipases), stirred at room temperature for 100 h
ViS (lmol"h#1"mL#1) ViR (lmol"h#1"mL#1) E (viS/viR)
Wild-type V235 0.42 0.04 11
V235A 1.10 0.004 274
V235C 1.09 0 >300
V235E 1.31 0.02 60
V235L 2.72 0.14 19
V235M 0.75 0 >300
V235N 1.01 0.02 67
V235S 1.12 0 >300
V235T 0.71 0 >300
new biocatalysts with enhanced activity and selectivity, suitable
for industrial applications.
4. Experimental
4.1. General
Peptone, tryptone, and yeast extract were purchased from Difco
(Paris, France), oleic acid from Prolabo (Fontenay sous Bois,
France). Racemic ibuprofen, racemic ketoprofen, (S)-naproxen
and other chemicals were purchased from Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MO).
4.2. Racemization of (S)-naproxen
The protocol used for the racemization of the (S)-naproxen is
described in earlier studies.31,32
4.3. Synthesis of ibuprofen, naproxen and ketoprofen ethyl
ester
The reactant (2.5 g of racemic ibuprofen, naproxen or ketopro-
fen) was mixed with EtOH (100 mL) ethanol and sulfuric acid
(1 mL). The mixture was stirred at 65 !C overnight. Then calcium
carbonate (2.5 g) was then added and the mixture was stirred
again for 30 min. The precipitate was removed by filtration and
the filtrate was dried under reduced pressure. The reaction was fol-
lowed by Thin Layer Chromatography analysis (TLC) using hexane/
isopropanol (99/1 v/v) as the eluent. 1H NMR spectra were
recorded on a Bruker AC-200.1 (200.1 MHz) spectrometer and con-
firmed the purity of both esters.
4.4. Construction of Lip2p variants by site-directed mutagenesis
Variants at position 88, 94, 97, 232 and 285 were previously
constructed54 and only the construction of variants targeting posi-
tion 235 was performed in the current work. JMP8 plasmid carry-
ing the wild-type LIP2 gene was previously described:58 LIP2
encoding the extracellular lipase Lip2p is under the transcriptional
control of the strong promoter POX2 inducible by oleic acid also
previously described.54 Mutagenesis in the LIP2 gene was per-
formed using the QuikChangeTM site-directed mutagenesis kit
(Stratagene). The following primers and their complementary
reverse counterparts were used for systematic directed mutagene-
sis at position 235: 50-CGTCCCTCAAXXXCCCTTCTGGG-30 with XXX
being GCC for V235A, TGC for V235C, GAC for V235D, GAG for
V235E, TTC for V235F, GGC for V235G, CAC for V235H, ATC for
V235I, AAG for V235K, CTC for V235L, ATG for V235M, AAC for
V235N, CCC for V235P, CAG for V235Q, CGA for V235R, TCC for
V235S, ACC for V235T, TGG for V235W, TAC for V235Y. Escherichia
coli DH5a was used as the host to produce the different plasmids
and sequences were controlled by sequencing (GATC, Konstanz,
Germany). Plasmids were digested by NotI and used for the trans-
formation of strain Y. lipolytica JMY121256 by the lithium acetate
method as described previously.62
4.5. Production and activity of lipases
The production of lipases from Y. lipolytica and C. rugosa is
described elsewhere.51,61 In order to increase the activity, the
obtained lipases can be concentrated using centrifugal filter units
(Amicon" Ultra Centrifugal Filters, Merck Millipore).
4.6. Enzymatic hydrolysis of ibuprofen, naproxen and
ketoprofen ethyl esters
In a 2 mL reactor (Eppendorf), 750 lL of culture supernatant (or
the concentrate supernatant) containing the enzyme and 750 lL of
racemic ethyl ibuprofen, naproxen or ketoprofen (50 mM in
decane) were added. The reactors were stirred in a vortex Genie
2 (D. Dutscher, Brumat, France) at room temperature for 100 h.
At regular time intervals, the progress of the reaction was moni-
tored by analyzing the organic phase composition after phase sep-
aration by centrifugation (dilution 1, 10 and 30 in hexane for the
ibuprofen, naproxen and ketoprofen ester, respectively).
4.7. Chromatography analysis
The HPLC device was equipped with a chiral column: Chiralcel
OJ-H (25 cm % 4.6 mm) (Chiral technologies Europe, Daicel group)
Table 4
Comparison of activity and selectivity of wild-type Lip2p lipase from Y. lipolytica and its variants during hydrolysis of (RS)-ketoprofen ethyl ester racemate. The hydrolysis was
performed in a biphasic medium:750 lL of decane containing 50 mM of ester racemate, 750 lL of enzyme supernatant (or the concentrate supernatant for CRL lipases), stirred at
room temperature for 100 h
viS viR E (viS/viR) or (viR/viS)
(lmol"h#1"mL#1) (lmol"h#1"mL#1)
Wild-type 0.11 0.16 1.5 (R)
V232A 0.11 0.04 2.91 (S)
V232F 0 0.40 >300 (R)
V232S 0.7 0.05 14 (S)
V235A 1.6 0.13 12 (S)
V235G 1.17 0.07 16 (S)
D97A-V232F 0 0.36 >300 (R)
Figure 5. Hydrolysis kinetics of (RS)-ketoprofen ethyl ester in a biphasic medium
(water:decane, 50:50, v/v) at ambient temperature. Wild-type lipase activity
towards the (S)- and (R)-enantiomers and variant V232F lipase activity towards
the (S)- and (R)-enantiomers. The hydrolysis was performed in a biphasic
medium:750 lL of decane containing 50 mM of ester racemate, 750 lL of enzyme
supernatant (or the concentrate supernatant for CRL lipases), stirred at room
temperature for 100 h.
connected to a UV detector (at 254 nm for the analysis of ibuprofen
ethyl ester and 270 nm for the naproxen ethyl ester). A flow rate of
1.0 mL/min was used. The mobile phase was composed of a mix-
ture n-hexane/isopropanol [98:2 v/v] for ibuprofen and naproxen
ethyl ester analysis. Retention time: 4/4.5 min for the (S)- and
(R)-enantiomers of ibuprofen ethyl ester and 20/22 min for the
(S)- and (R)-enantiomers of naproxen ethyl ester. Ibuprofen formed
during the reaction and remaining in the decane phase can be ana-
lyzed in the same conditions as ibuprofen ethyl ester, the retention
time being 7/8 min for the (S)- and (R)-enantiomers of ibuprofen,
respectively.
For the analysis of ketoprofen ethyl ester the mobile phase was
composed only of hexane, with retention times of 12 and 13 min
for the (S)- and (R)-enantiomer respectively.
4.8. Determination of enantioselectivity (E)
E ¼
viS
viR
or
E ¼
viR
viS
where viS and R are the initial rates of hydrolysis of the (S)- and (R)-
enantiomers respectively.
4.9. Molecular modelling studies
Since the only available crystallographic structure of Y. lipolytica
Lip2p corresponds to a closed inactive conformation of the
enzyme,63we used an homology model of the open conformation54
to perform docking of the ligands in the catalytic site. Three-
dimensional models of the covalent tetrahedral intermediates for
each enantiomer (S)- and (R)-enantiomers of ibuprofen and
naproxen ethyl esters, respectively, were built. Each enantiomer
was placed in the active site so that it is covalently bonded to
the catalytic serine (S162) and fulfills the hydrogen bonding inter-
actions required for productive catalysis. Models of enzyme vari-
ants mutated at positions 232 or 235 were constructed from the
model of wild type Lip2p by introducing site mutations using the
mutator module in VMD.64 Each enzyme variant was then mini-
mized using parm99sb-ildn force field65 in Gromacs software.66
The covalent docking of the enantiomers was carried out using
Autodock program.67 The conformational space explored during
docking was defined by a grid centered on Ser162 sidechain and
spacing by 0.375 Å. Autodock parameters were set to the standard
values for genetic algorithm and 200 docking poses were extracted.
These poses were clustered based on their RMSD. One ligand con-
formation representative of the best cluster was placed in wild-
type Lip2p or its enzyme variants and the whole system was min-
imized until the maximum force was less than 100 kJ"mol#1. Visu-
alization and graphics were done using VMD software.64
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